Citations

Showing 10 of 108094 citations.

Early Versus Usual Palliative Care Consultation in the Intensive Care Unit
Helgeson, Scott A. , Burnside, Rebecca, Robinson, Maisha T. , Mack, Rachel C., Ball, Colleen T. , Moss, John E. , Helgeson, Scott A , Guru, Pramod

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | July 14, 2022 | Volume: 40 | Issue: 5 | Pages: 544-551

10.1177/10499091221115732 | PMID 35833450 Get It

Objectives Palliative Medicine involvement in MICU patients have improved length of stay and mortality, but with varying effects on specific patient decision outcomes, such as, advance care planning. These studies have utilized Palliative Medicine later in the hospital or ICU course, with some evidence showing that earlier involvement resulted in better results. The purpose of this study was to evaluate the benefits of early (within 24 hours) palliative care consultation in medical ICU (MICU) patients to clinical and satisfaction outcomes. Methods An unblinded randomized study performed in the MICU in one academic hospital in the USA. Ninety-one adult patients admitted to MICU received a Palliative care medicine consultation within 24 hours as the intervention. Measurements and results Ninety-one patients admitted to the MICU underwent randomization with 50 patients randomly assigned to receive Palliative Medicine consultation and 41 patients randomly assigned to receive standard-of-care based on predefined criteria. The median satisfaction score was 23 points higher for the patients in the intervention group (P < .001). The median length of MICU stay was 5 days shorter in the intervention group compared to the control group (95% CI; 1 day to 18 days, P = .018). Advance care planning was completed in the hospital for 34% of patients in the intervention arm and 12% of patients in the controls arm (absolute risk difference 22%, 95% CI 4% to 37%, P = .016). Conclusion Early Palliative Medicine consultation within 24 hours of MICU admission showed significant benefits to patients by improving satisfaction and decreasing length of stay. This study provides evidence that Palliative Medicine involvement earlier in the course of severe disease is important. Further studies in other types of intensive care units (neurological and Cardiovascular) are necessary to determine their impact.
A multidisciplinary approach to the management of brachial plexus injuries: experience from the Mayo Clinic over 100 years
Shin, Alexander Y. , Loosbroch, Michelle F., Spinner, Robert J. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Journal of Hand Surgery (European Volume) | July 14, 2022 | Volume: 47 | Issue: 11 | Pages: 1103-1113

10.1177/17531934221110733 | PMID 35833214 Get It

A multidisciplinary brachial plexus clinic has been a relatively new concept, offering different surgical speciality perspectives on the treatment of brachial plexus injuries. The resulting collaborative effort has proven to be greater than the sum of its parts. In this review, the history, philosophy of care, development/implementation and impact of a creation of a multidisciplinary brachial plexus team at the Mayo Clinic are detailed.
Blood Flow Restriction Therapy for 2 Weeks Prior to Anterior Cruciate Ligament Reconstruction Did Not Impact Quadriceps Strength Compared to Standard Therapy
Tramer, Joseph S. , Khalil, Lafi S. , Jildeh, Toufic R. , McGee, Anna , Lau, Michael J., Moutzouros, Vasilios , Okoroha, Kelechi R. , Abbas, Muhammad J.

Mayo Clinic

Arthroscopy | July 13, 2022 | Volume: 39 | Issue: 2 | Pages: 373-381

10.1016/j.arthro.2022.06.027 | PMID 35842062 Get It

Purpose To evaluate the efficacy of a 2‐week home‐based blood flow restriction (BFR) prehabiliation program on quadriceps strength and patient‐reported outcomes prior to anterior cruciate ligament (ACL) reconstruction. Methods Patients presenting with an ACL tear were randomized into two groups, BFR and control, at their initial clinic visit. Quadriceps strength was measured using a handheld dynamometer in order to calculate peak force, average force, and time to peak force during seated leg extension at the initial clinic visit and repeated on the day of surgery. All patients were provided education on standardized exercises to be performed 5 days per week for 2 weeks between the initial clinic visit and date of surgery. The BFR group was instructed to perform these exercises with a pneumatic cuff set to 80% of limb occlusion pressure placed over the proximal thigh. Patient‐Reported Outcome Measurement System Physical Function (PROMIS‐PF), knee range of motion, and quadriceps circumference were gathered at the initial clinic visit and day of surgery, and patients were monitored for adverse effects. Results A total 45 patients met inclusion criteria and elected to participate. There were 23 patients randomized to the BFR group and 22 patients randomized into the control group. No significant differences were noted between the BFR and control groups in any demographic characteristics (48% vs 64% male [ P = .271] and average age 26.5 ± 12.0 vs 27.0 ± 11.0 [ P = .879] in BFR and control, respectively). During the initial clinic visit, there were no significant differences in quadriceps circumference, peak quadriceps force generation, time to peak force, average force, pain, and PROMIS scales ( P > .05 for all). Following completion of a 2‐week home prehabilitation protocol, all patients indeterminant of cohort demonstrated decreased strength loss in the operative leg compared to the nonoperative leg ( P < .05 for both) However, there were no significant differences in any strength or outcome measures between the BFR and control groups ( P > .05 for all). There were no complications experienced in either group, and both were compliant with the home‐based prehabilitation program. Conclusions A 2‐week standardized prehabilitation protocol preceding ACL reconstruction resulted in a significant improvement in personal quadriceps peak force measurements, both with and without the use of BFR. No difference in quadriceps circumference, strength, or patient reported outcomes were found between the BFR and the control group. The home‐based BFR prehabiliation protocol was found to be feasible, accessible, and well tolerated by patients. Level of Evidence Level II, randomized controlled trial with small effect size
Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
Koehler, Viktoria Florentine , Adam, Pia , Fuß, Carmina Teresa , Jiang, Linmiao , Berg, Elke, Frank‐Raue, Karin, Raue, Friedhelm , Hoster, Eva , Knösel, Thomas , Schildhaus, Hans‐Ulrich , Negele, Thomas, Siebolts, Udo , Allelein, Stephanie, Spitzweg, Christine , Kroiß, Matthias , Kroiss, Matthias , Koehler, Viktoria F , Hoster, Eva , Lorenz, Kerstin , Schott, Matthias

Mayo Clinic

Cancers | July 13, 2022 | Volume: 14 | Issue: 14 | Pages: 3405

10.3390/cancers14143405 | PMID 35884466 Get It

Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32–NR (not reached); n = 36), and the median PFS was 21 months (12–39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13–79; n = 22), and the median PFS was 3.5 months (2–14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.
Bullous Erythema ab Igne Unexpected Biopsy: Challenge
Pincelli, Thaís , Keeling, James , Sokumbi, Olayemi , Pincelli, T

Mayo Clinic

The American Journal of Dermatopathology | July 13, 2022 | Volume: 44 | Issue: 8 | Pages: e86-e87

10.1097/dad.0000000000002243 | PMID 35830705 Get It

Bullous Erythema ab Igne Unexpected Biopsy: Answer
Pincelli, Thaís , Keeling, James , Sokumbi, Olayemi , Pincelli, T

Mayo Clinic

The American Journal of Dermatopathology | July 13, 2022 | Volume: 44 | Issue: 8 | Pages: 615-615

10.1097/dad.0000000000002242 | PMID 35830702 Get It

NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022
Wood, Douglas E. , Kazerooni, Ella A. , Eapen, Georgie A. , Ettinger, David S. , Ferguson, J. Scott , Hou, Lifang , Kadaria, Dipen, Klippenstein, Donald, Lackner, Rudy P., Lennes, Inga T. , Leung, Ann N. , Mazzone, Peter J. , Merritt, Robert E. , Midthun, David E. , Onaitis, Mark W. , Pipavath, Sudhakar, Pratt, Christie, Puri, Varun , Raz, Dan J. , Reddy, Chakravarthy, Reid, Mary E. , Sandler, Kim L. , Tanoue, Lynn, Tong, Betty C. , Wei, Benjamin , Westover, Kenneth D. , Yang, Stephen C. , McCullough, Beth, Hughes, Miranda, Hou, Lifang , Leung, Ann , Aberle, Denise R. , Berman, Abigail T. , Brown, Lisa Marie , Kumar, Rohit , Leard, Lorriana E. , Pratt, Christie, Sands, Jacob , Schabath, Matthew B. , Studts, Jamie L. , Travis, William D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 754-764

10.6004/jnccn.2022.0036 | PMID 35830884 Get It

The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Phage Particles of Controlled Length and Genome for In Vivo Targeted Glioblastoma Imaging and Therapeutic Delivery
Tsedev, Uyanga , Lin, Ching‐Wei , Lam, Fred C. , Belcher, Angela M. , Belcher, Angela M , Hess, Gaelen T. , Sarkaria, Jann N.

Mayo Clinic

ACS Nano | July 13, 2022 | Volume: 16 | Issue: 8 | Pages: 11676-11691

10.1021/acsnano.1c08720 | PMID 35830573 Get It

Uric Acid Expression in Carotid Atherosclerotic Plaque and Serum Uric Acid Are Associated With Cerebrovascular Events
Nardi, Valentina , Franchi, Federico , Prasad, Megha , Fatica, Erica M. , Alexander, Mariam P., Bois, Melanie C. , Lam, Josephine, Meyer, Fredric B. , Lanzino, Giuseppe , Xiong, Yuning, Lerman, Lilach O. , Lanzino, Giuseppe , Lerman, Lilach O , Nardi, Valentina , Singh, Ravinder J. , Lutgens, Esther , Lerman, Amir

Mayo Clinic

Hypertension | July 13, 2022 | Volume: 79 | Issue: 8 | Pages: 1814-1823

10.1161/hypertensionaha.122.19247 | PMID 35656807 Get It

Background: Uric acid (UA) concentration within carotid plaque and its association with cerebrovascular events have not been detected or quantified. Systemically, serum UA is a marker of inflammation and risk factor for atherosclerosis. However, its association with carotid plaque instability and stroke pathogenesis remains unclear. In patients undergoing carotid endarterectomy, we aimed to determine whether UA is present differentially in symptomatic versus asymptomatic carotid plaques and whether serum UA is associated with cerebrovascular symptoms (stroke, transient ischemic attack, or amaurosis fugax). Methods: Carotid atherosclerotic plaques were collected during carotid endarterectomy. The presence of UA was assessed using Gomori methenamine silver staining as well as anti-UA immunohistochemical staining and its quantity measured using an enzymatic colorimetric assay. Clinical information was obtained through a retrospective review of data. Results: UA was more commonly detected in symptomatic (n=23) compared with asymptomatic (n=9) carotid plaques by Gomori methenamine silver (20 [86.9%] versus 2 [22.2%]; P =0.001) and anti-UA immunohistochemistry (16 [69.5%] versus 1 [11.1%]; P =0.004). UA concentration was higher in symptomatic rather than asymptomatic plaques (25.1 [9.5] versus 17.9 [3.8] µg/g; P =0.021). Before carotid endarterectomy, serum UA levels were higher in symptomatic (n=341) compared with asymptomatic (n=146) patients (5.9 [interquartile range, 4.6–6.9] mg/dL versus 5.2 [interquartile range, 4.6–6.2] mg/dL; P =0.009). Conclusions: The current study supports a potential role of UA as a potential tissue participant and a systemic biomarker in the pathogenesis of carotid atherosclerosis. UA may provide a mechanistic explanation for plaque instability and subsequent ischemic cerebrovascular events.